Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
104.40    1.20 (1.16%)
Bid:
104.40
Ask:
105.20
Spread: 0.80 (0.766%)
Market Cap: £171.16m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

17 May 2012 07:00

RNS Number : 5270D
Yule Catto & Co PLC
17 May 2012
 



 17 May 2012

 

Yule Catto & Co plc (the "Group") 

 

AGM & Interim Management Statement

 

At this morning's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter Wood will make the following statement which also comprises the Group's interim management statement for the period 1 January 2012 to date.

 

Profitability for the period was substantially ahead of prior year* and in line with the Board's expectations, in what has been a very challenging environment. The economic issues, particularly in Europe, have produced an environment of high raw material volatility and a general lack of business confidence.

 

In our Europe and North America segment, volumes in Q1 were 11% below what was a strong start to 2011, but 14% ahead of Q4 2011. Weakness was most evident in sales to the construction sector. Margin management has more than compensated for the lower volume levels, and together with the benefit of the planned synergies, the segment operating profit was substantially ahead of prior year.

 

In our Asia and ROW segment, the Construction and Coatings business unit showed good year on year improvement. However, in Health and Protection, demand remained subdued. Asia and ROW volumes were down 1% on Q1 2011 and 11 % ahead of Q4 2011. Margins in Health and Protection in the first half of 2011 were reasonably strong and have not been maintained at these high levels. Consequently results overall for the segment were below prior year.

 

Synergies hit an annualised run rate of £20 million as at the end of Marchand remain on track for £25M at the end of Q1 next year. This represents a £15M full year synergy benefit to 2012 operating profits compared to prior year.

 

The Group's latex expansion in Malaysia remains on track for production in the fourth quarter. This expansion will allow us to keep pace with long term demand in the high growth nitrile latex market and allow additional growth through the sale of locally manufactured SBR.

 

Net debt at the end of April was £171M, slightly up on the year end position of £164M

 

The Board also notes the current weakness of the euro which has hit 1.25 against sterling in recent days, having averaged 1.20 over the first four months of 2012, and 1.15 through 2011. The Group made a little over half of its operating profit in the euro zone in 2011. The translation effect of a one cent movement in the euro equates to approximately £0.5M of operating profit.

 

The environment remains both challenging and volatile. Against this background, the Board is pleased with the Group's financial performance year to date, and its expectations for the performance of the Group over the remainder of the year remain unchanged.

 

Note: * The Group reported an underlying proforma PBT of £96.0M for full year 2011, which included an adjustment to reflect the first quarter's pre acquisition operating profit of PolymerLatex of £13.3M and an estimated interest cost of £2.1M. Comments on PBT, operating profit performance and volumes for the period under review compared to 2011 are based on this proforma basis.

 

- Ends -

 

ENQUIRIES:

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

 

David Blackwood, Group Finance Director

 

 

 

 

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

 

John Olsen

 

Ian Payne

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLFFELEVIRLIF
Date   Source Headline
17th May 20077:01 amRNSAGM Statement
15th May 20074:29 pmRNSAnnual Report and Accounts
20th Apr 20079:40 amRNSAnnual Information Update
19th Apr 200712:47 pmRNSHolding(s) in Company
10th Apr 20075:26 pmRNSDirectorate Change
29th Mar 20074:37 pmRNSHolding(s) in Company
22nd Mar 200712:30 pmRNSDirectorate Change
12th Mar 20071:05 pmRNSDirector/PDMR Shareholding
12th Mar 20071:00 pmRNSDirector/PDMR Shareholding
7th Mar 20077:01 amRNSFinal Results
6th Mar 20074:04 pmRNSHolding(s) in Company
20th Feb 20074:29 pmRNSNotice of Results
1st Feb 20074:23 pmRNSBlocklisting Interim Review
18th Dec 20062:08 pmRNSVoting Rights and Capital
15th Dec 20067:58 amRNSTrading Statement
4th Dec 200612:49 pmRNSBlocklisting Interim Review
12th Oct 200610:46 amRNSHolding(s) in Company
2nd Oct 20063:20 pmRNSDirector/PDMR Shareholding
8th Sep 20069:01 amRNSDirector/PDMR Shareholding
7th Sep 20067:01 amRNSInterim Results
21st Aug 20063:22 pmRNSNotice of Results
21st Aug 20062:41 pmRNSDirectorate Change
1st Aug 20062:51 pmRNSBlocklisting Interim Review
14th Jul 20063:51 pmRNSNew Chief Executive
7th Jun 200611:14 amRNSDirector/PDMR Shareholding
5th Jun 20067:00 amRNSDisposal of Reabrook Limited
1st Jun 20064:48 pmRNSBlocklisting Interim Review
25th May 20063:11 pmRNSDirector/PDMR Shareholding
25th May 20063:09 pmRNSDirector/PDMR Shareholding
18th May 20064:59 pmRNSResult of AGM
18th May 200612:00 pmRNSAGM Statement
3rd May 200612:28 pmRNSAnnual Information Update
18th Apr 20063:49 pmRNSAnnual Report and Accounts
13th Apr 200611:30 amRNSDirector/PDMR Shareholding
13th Apr 200611:28 amRNSDirector/PDMR Shareholding
21st Mar 200612:05 pmRNSDirector/PDMR Shareholding
16th Mar 20067:01 amRNSFinal Results
20th Feb 20063:44 pmRNSHolding(s) in Company
20th Feb 20062:00 pmRNSAppointment
9th Feb 200612:10 pmRNSNotice of Results
31st Jan 200610:00 amRNSAdditional Listing
30th Dec 200512:00 pmRNSWithdrawal from SO2 business
23rd Dec 200510:14 amRNSDirector/PDMR Shareholding
14th Dec 20057:00 amRNSPre-close Trading Statement
8th Dec 20051:29 pmRNSBlocklisting Interim Review
7th Dec 20058:42 amRNSSale of Autoclenz Limited
7th Dec 20057:01 amRNSAdmission to trading on AIM
6th Dec 20054:23 pmRNSDirector Declaration
6th Dec 20054:18 pmRNSDirectorate Change
2nd Dec 200510:07 amRNSSale of Autoclenz Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.